搜索筛选:
搜索耗时1.1435秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
发布年度:
[期刊论文] 作者:Krystyna Serkies,Jacek Jassem,
来源:中国癌症研究:英文版 年份:2018
...
Cabazitaxel vs docetaxel in chemotherapy-naive(CN)patients with metastatic castrationresistant prost
[会议论文] 作者:Stephane Oudard,Lisa Sengelov,Gedske Daugaard,Fred Saad,Steinbjoern Hansen,Marie Hjelm-Eriksson,Jacek Jassem,
来源:2016年临床肿瘤学新进展学术研讨会 年份:2016
...
Analysis of KRAS/NRAS and BRAF Mutations in the Phase 3 PRIME Study of Panitumumab+FOLFOX4 vs.FOLFOX
[会议论文] 作者:Siena,Josep Tabernero,Ronald Burkes,Mario Barugel,Yves Humblet,Gyorgy Bodoky,David Cunningham,Jacek Jassem,
来源:第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份:2013
Background: Analysis of a phase 3 panitumumab monotherapy study suggested that KRAS and NRAS mutations beyond KRAS exon 2 may be predictive of panitumumab efficacy (Peeters M,et al.Clin Cancer Res 201...
Randomized phase Ⅱ, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (
[会议论文] 作者:Molina,Timothy Eisen,Jacek Jassem,Jakub Zolnierek,Pablo Maroto,Begona Mellado,Bohuslav Melichar,Jiri,
来源:2015年临床肿瘤学新进展学术研讨会 年份:2015
...
[会议论文] 作者:Siena,Josep Tabernero,Ronald Burkes,Mario Barugel,Yves Humblet,Gyorgy Bodoky,David Cunningham,Jacek Jassem,
来源:第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份:2013
目的: The primary and final analyses of PRIME demonstrated that panitumumab+FOLFOX4 significantly improved progression-free survival (PFS) vs.FOLFOX4 alone for 1st-line treatment of patients with wild-t...
相关搜索: